Literature DB >> 33607309

Global Patterns and Trends in Lung Cancer Incidence: A Population-Based Study.

Yanting Zhang1, Ganfeng Luo2, Jaione Etxeberria3, Yuantao Hao4.   

Abstract

INTRODUCTION: Lung cancer (LC) has been the most common cancer worldwide for several decades. This study comprehensively examines recent geographic patterns and temporal trends in LC incidence from 1978 to 2012 in 43 countries and evaluates the effects of birth cohort and period on temporal trends.
METHODS: Data were retrieved from the Cancer Incidence in Five Continents database. Joinpoint regression and age-period-cohort models were applied.
RESULTS: The age-standardized rate was highest in Turkey (69.3 per 100,000 person-years) for men and in Denmark (36.7) for women in the period 2008 to 2012. Sex disparities were noted in most countries. From 1978 to 2012, a total of 19 countries had significantly declining trends among men, whereas 26 countries had significantly increasing trends among women (all p < 0.05). Quasi-reversed V-shaped and U-shaped incidence rate ratio trends indicating birth cohort effects were detected in 26 countries for men, with the highest risks mainly occurring in the 1930 to 1950 birth cohorts. However, the risks among recent generations have moderately increased in the People's Republic of China and Japan for men and sharply increased in Lithuania, Belarus, and Republic of Korea for women. Incidence rate ratio increases were steep among earlier birth cohorts and gradual among the post-1930s cohorts in 15 countries for women. Period effects were more evident than birth cohort effects in five countries for both sexes.
CONCLUSIONS: Disparities in LC incidence and carcinogenic risk persist worldwide. Our findings identified high-risk target populations for primary prevention to reduce the LC incidence and highlighted the urgent need for etiologic studies to identify the reasons for pronounced cohort-specific risk increases in certain countries.
Copyright © 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Birth cohort effect; Global trends; Incidence; Lung cancer; Period effect

Year:  2021        PMID: 33607309     DOI: 10.1016/j.jtho.2021.01.1626

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  11 in total

1.  Assessment of age, period, and cohort effects of lung cancer incidence in Hong Kong and projection up to 2030 based on changing demographics.

Authors:  Jianqiang Du; Haifeng Sun; Yuying Sun; Jianfei Du; Wangnan Cao; Shengzhi Sun
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

2.  Gender disparities in incidence and projections of lung cancer in China and the United States from 1978 to 2032: an age-period-cohort analysis.

Authors:  Min Jiang; Cairong Zhu; Minghan Xu; Mandi Li; Jiao Pei; Chenyao Wu; Lin Jiang
Journal:  Cancer Causes Control       Date:  2022-08-02       Impact factor: 2.532

3.  Evaluation of Exudative Pleural Effusions: A Multicenter, Prospective, Observational Study.

Authors:  Guntulu Ak; Selma Metintas; Ayse Naz Taskın; Melahat Uzel Sener; Yasemin Soyler; Meltem Yilmaz; Akif Turna; Pınar Akin Kabalak; Semra Bilaceroglu; Deniz Koksal; Nilgun Yilmaz Demirci; Ozlem Sogukpinar; Sibel Boga; Merve Ercelik; Gulistan Karadeniz; Gulru Polat; Filiz Guldaval; Ulku Aka Akturk; Senay Yilmaz; Nalan Ogan; Saliha Yilmaz; Dorina Esendagli; Benan Caglayan; Arife Zeybek; Nagihan Durmus Kocak; Pinar Mutlu; Cansel Atinkaya Baytemir; Ismail Sarbay; Ulku Yilmaz; Muzaffer Metintas
Journal:  Lung       Date:  2022-09-29       Impact factor: 3.777

4.  Predictive value of intratumor metabolic and heterogeneity parameters on [18F]FDG PET/CT for EGFR mutations in patients with lung adenocarcinoma.

Authors:  Ming Ni; Shicun Wang; Xin Liu; Qin Shi; Xingxing Zhu; Yifan Zhang; Qiang Xie; Weifu Lv
Journal:  Jpn J Radiol       Date:  2022-10-11       Impact factor: 2.701

5.  CDC25C as a Predictive Biomarker for Immune Checkpoint Inhibitors in Patients With Lung Adenocarcinoma.

Authors:  Wengang Zhang; Xiaoling Shang; Fei Yang; Wenfei Han; Handai Xia; Ni Liu; Yanguo Liu; Xiuwen Wang
Journal:  Front Oncol       Date:  2022-04-29       Impact factor: 5.738

6.  Identification of sSIGLEC5 and sLAG3 as New Relapse Predictors in Lung Cancer.

Authors:  Karla Montalbán-Hernández; José Carlos Casalvilla-Dueñas; Patricia Cruz-Castellanos; Laura Gutierrez-Sainz; Roberto Lozano-Rodríguez; José Avendaño-Ortiz; Carlos Del Fresno; Javier de Castro-Carpeño; Eduardo López-Collazo
Journal:  Biomedicines       Date:  2022-04-30

7.  Comprehensive Analysis of Programmed Cell Death Signature in the Prognosis, Tumor Microenvironment and Drug Sensitivity in Lung Adenocarcinoma.

Authors:  Shize Pan; Heng Meng; Tao Fan; Bo Hao; Congkuan Song; Donghang Li; Ning Li; Qing Geng
Journal:  Front Genet       Date:  2022-05-18       Impact factor: 4.772

8.  Immune Checkpoints OX40 and OX40L in Small-Cell Lung Cancer: Predict Prognosis and Modulate Immune Microenvironment.

Authors:  Peixin Chen; Hao Wang; Lishu Zhao; Haoyue Guo; Liping Zhang; Wei Zhang; Chenglong Sun; Sha Zhao; Wei Li; Jun Zhu; Jia Yu; Chunyan Wu; Yayi He
Journal:  Front Oncol       Date:  2021-11-25       Impact factor: 6.244

9.  International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials.

Authors:  Matthew P Smeltzer; Giorgio V Scagliotti; Heather A Wakelee; Tetsuya Mitsudomi; Upal Basu Roy; Russell C Clark; Renee Arndt; Clayton D Pruett; Karen L Kelly; Peter Ujhazy; Melissa L Johnson; Yesim Eralp; Carlos H Barrios; Fabrice Barlesi; Fred R Hirsch; Paul A Bunn
Journal:  J Thorac Oncol       Date:  2022-02-17       Impact factor: 20.121

10.  [Analysis on the Incidence and Economic Burden of Patients with Lung Cancer].

Authors:  Guo Tian; Li Bian; Xiaoli Xu; Shumei Li
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2022-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.